Bristol Myers (BMY) Stock: Here’s What You Need To Know

Bristol Myers (NYSE:BMY) On August 5, 2016 Bristol Myers had a very rough day with respect to one of its targets in the pipeline. ┬áThe company’s PD-1 immune checkpoint inhibitor, known as Opdivo, failed to meet the primary endpoint of a phase 3 clinical trial. Bristol Myer’s stock did not have a good day after … Read more

Bind Therapeutics (BIND) Stock: Heres What You Need To Know

Bind Therapeutics (NASDAQ:BIND) On July 1, 2016 Bind Therapeutics announced that it had agreed to a stalking horse bid from Pfizer. The company said that it had filed a motion in court for a purchase agreement whereby Pfizer would acquire Bind’s assets. Investors greatly cheered this news and the stock nearly doubled to 0.78 cents … Read more

Biotech Stock News (AZN) (AMGN) (NVS) (LLY) (HRTX) (MRK)

AstraZeneca (NYSE:AZN) & Amgen (NASDAQ:AMGN) On May 26, 2015 both AstraZeneca and Amgen announced that it would end a partnership established back in 2012 for a psoriasis drug collaboration. This collaboration established in 2012 allowed Astrazeneca to work on five antibody compounds from Amgen’s anti-inflammation drug pipeline. Amgen received an upfront payment of at least … Read more

Biotech Stock News (CLDN) (BLUE) (QURE) (ONCE) (CANF) (AMGN) (MRK) (BMY)

Celladon Corporation (NASDAQ:CLDN) On April 26, 2015 Shares of Celladon Corporation tumbled 80% in one day after the company reported that its phase 2 trial using Mydicar to treat heart failure patients failed to meet on both the primary endpoint and the secondary endpoint. The phase 2 trial was known as CUPID-2 and recruited up … Read more

Biotech Stock News (HZNP)(HPTX)(XON)(SRPT)(MDVN)(ALPMY)(AZN)

Horizon Pharma (NASDAQ:HZNP) Shares of Horizon Pharma ended the day up 18% on March 30, 2015 after the company announced that it would acquire Hyperion Therapeutics (NASDAQ:HPTX) for $955.7 million dollars. Although one thing to note is that this deal for $955.7 million dollars will be a mix of a cash and debt deal. The … Read more

Biotech Stock News (RXII) (MRK) (BMY) (CNAT) (ICPT)

Rxi Pharmaceuticals Corp (NASDAQ: RXII) Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported ┬ápositive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. … Read more